Thermo Fisher Scientific acquires PeproTech for US $1.85 bn
PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products
PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products
He has over 29 years of experience in the field of manufacturing, R&D, business and customer service management
The latest research results indicated that JMB2002 had high binding activity to the Omicron variant and showed potent Omicron pseudovirus neutralization function
The Academy endeavours to reach all levels of the society in creating programs that are accessible to one and all with training for Health Volunteers, Asha, Angavadi, school-teachers and students as part of life-skill development
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
The virtual world makes it possible to visualize, test, understand and predict what cannot be seen, before a patient is treated
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel
The first pilot study from India analyzing Covaxin-Covishield mixed doses
Partnering to build biosynthesis processes and a pharmaceutical production platform
Subscribe To Our Newsletter & Stay Updated